Microalbuminuria, endocrinal metabolic disorders as predictors of hypertension

The present work aimed to study microalbuminuria, endocrinal and metabolic disorders that may predict hypertension. One hundred and thirty subjects were classified into three groups; group I patients with essential hypertension [50 patients], group II normotensive offsprings with family history of hypertension [50 subjects] and group III healthy normotensive subjects [30 subjects]. The study confirmed that many of the components of hypertension syndrome as metabolic abnormalities [increased total cholesterol, LDL-cholesterol, triglycerides and hyperhomocysteinemia], renal abnormalities [microalbuminuria] and endocrinal abnormalities [increased plasma insulin, norepinephrine, renin and endothelin levels] precede the onset of high blood pressure. So, early identification and treatment of them will have a more significant impact on the course of the disease

Sirolimus based therapy in live donor renal transplantation: a prospective randomized study

The present work aimed to study safety and efficacy of sirolimus in combination with either low dose tacrolimus or mycophenolate mofetil in live donor kidney transplant recipients. A total of 80 patients of either sex aging >/18 years with end-stage renal disease who had undergone live donor renal allotransplantation were recruited into the study. They were randomly divided into two groups. Group A patients received sirolimus in dose of 10 mg/day for 3 days after surgery then maintained on 5 mg/day. In addition, they received tacrolimus and steroids. Group B patients received sirolimus in dose of 10 mg/day, mycophenolate mofetil and steroids. All patients were followed up for 12 months clinically and by laboratory, radiologic and histopathologic evaluation. The study showed that excellent one year kidney transplant outcomes can be achieved by sirolimus administration especially with avoidance of calcineurin inhibitors. Longer follow-up is required to study the impact on graft integrity and eventual graft survival and chronic rejection rates